15th June 2026

dorsaVi Well Funded after $500,000 Options Exercise by Major Shareholders

Key Highlights:

- **$500,000 received:** The Company has received valid exercises of 25,000,000 unlisted options.
- **Strong shareholder alignment:** 22,000,000 shares will be subject to a 6-month voluntary escrow, demonstrating long-term confidence in the Company's strategy and future growth prospects.
- **Company continues to be well funded**: with the pre-tape out work complete and formal design review being scheduled for June 2026 [1] the Company will accelerate further development & commercialisation of its ultra-edge AI, RRAM neuromorphic semiconductor technologies, and human-robot collaboration platform, which will be the primary focus for the remainder of CY2026.
- **Commercialisation strategy accelerated:** The 22nm node delivers higher cell density, lower energy per operation, and improved thermal robustness compared with 180nm. These gains bring exoskeletons, prosthetics, medical implants, and industrial robotics into commercial scope.

Melbourne, Australia, 15 June 2026 – dorsaVi Limited (ASX: DVL) ("dorsaVi" or "the Company") a technology innovator across advanced edge AI, neuromorphic computing, and human movement analytics, is pleased to announce that holders of 25,000,000 unlisted options have exercised their options, raising $500,000.

Of the 25,000,000 shares to be issued on exercise of the Unlisted Options (Exercise Shares), 22,000,000 shares will be subject to voluntary escrow for a period of 6 months from the date of issue, as agreed with the relevant holders.

The proceeds will be deployed to further strengthen the development of the Company's key technologies, including its RRAM neuromorphic computing platform, ultra-edge AI capabilities, and human-robot collaboration IP acquired from Nanyang Technological University.

Chairman Commentary

Gernot Abl, Chairman of dorsaVi, commented:

"We are very pleased with the support demonstrated by our option holders through the exercise of these options. The additional funding positions dorsaVi well to execute on our technology roadmap and advance our commercialisation initiatives across defence, industrial, and medical markets. We look forward to the significant milestones ahead as we enter this next phase of the Company's growth."

This announcement has been authorised for release by the Board of Directors.

-ENDS-

[1] ASX Announcement 18 May 2026

Mathew Regan **Group Chief Executive Officer** **+61 427 477 298** **Email: mregan@dorsaVi.com**	**Gernot Abl** **Chairman** **+61 419 802 653** **Email: ga@dorsaVi.com**

Forward-Looking Statements

This announcement may contain certain forward-looking statements and projections. Such forward-looking statements/projections are estimates for discussion purposes only and should not be relied upon. Forward looking statements/projections are inherently uncertain and may therefore differ materially from results ultimately achieved. dorsaVi Limited does not make any representations and provides no warranties concerning the accuracy of the projections and disclaims any obligation to update or revise any forward-looking statements/projections based on new information, future events or otherwise, except to the extent required by applicable laws.

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on delivering intelligence at the ultra-edge. Enabling real time AI-driven decisions to be made locally, at the point of sensing, without reliance on cloud connectivity. dorsaVi's wearable sensor technology captures, quantifies, and assesses detailed human movement and position outside a biomechanics lab, in both real-time and real situations for up to 24 hours, across clinical applications, elite sports, and occupational health and safety. Underpinning this vision, dorsaVi is building the hardware foundations of the ultra-edge through strategic investments in neuromorphic computing and RRAM memory technology. dorsaVi's focus is on three major markets:

- Ultra-Edge Intelligence: dorsaVi's sensor platforms are designed to process and act on data locally, embedding AI-driven inference directly at the point of capture. By investing in neuromorphic computing and RRAM memory technology, dorsaVi enables real-time decision-making without round-tripping to the cloud, delivering lower latency, lower power consumption, and reliable operation in latency- and connectivity-constrained environments across industrial, clinical, and autonomous systems applications.

- Workplace: dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral Resources and BHP.

- Clinical: dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com.